Taurine and Atrial Fibrillation

Overview

Taurine is a sulfur‑containing amino acid present in high concentrations in the heart. It participates in calcium handling, osmoregulation, membrane stabilization, and modulation of autonomic tone. In the context of atrial fibrillation (AFib), taurine has attracted interest because it may stabilize cardiac electrophysiology and mitigate atrial remodeling. While human randomized AF trials are lacking, preclinical studies and case observations provide biologically plausible signals. This page summarizes mechanisms, evidence, dosage considerations, and safety. Use these insights to have an informed discussion with your cardiology team.

How Taurine Might Help in AFib

1) Electrophysiology and ion homeostasis

AFib is sustained by abnormal conduction and refractoriness. Taurine modulates intracellular Ca²⁺ handling and supports potassium balance, which can dampen afterdepolarizations and reduce ectopy. Animal models show shorter AF duration and normalization of channel expression when taurine is provided.

2) Structural remodeling

Chronic AF is maintained by structural changes including fibrosis, inflammation, and atrial dilation. In rat AF models, taurine reduced fibrosis and inflammatory signaling and limited dilation—changes that typically make AF more persistent. Protecting the atrial substrate is a key preventive strategy alongside rhythm control.

3) Autonomic balance

Sympathetic predominance and vagal triggers both play roles in AF. Experimental work suggests taurine can help restore sympatho‑vagal balance after myocardial injury, potentially decreasing arrhythmia vulnerability. Practical implications include pairing taurine with sleep, stress, and lifestyle optimization (see Triggers).

Evidence Summary

Evidence to date spans preclinical models and small human observations. Highlights include:

• Electrical remodeling: In acetylcholine–CaCl₂ rat AF models, taurine shortened AF duration and normalized ion‑channel mRNA and potassium levels.
• Structural remodeling: Companion studies showed reduced atrial fibrosis, inflammation, and dilation with taurine supplementation.
• Autonomic effects: Taurine helped restore autonomic balance and reduced arrhythmia susceptibility in injury models.
• Human case reports: Oral taurine (sometimes with L‑arginine) was associated with reductions in premature beats (PACs/PVCs) in individuals with frequent ectopy. These are not controlled AF trials but suggest rhythm‑stabilizing potential.

Explore the primary citations in the site’s Research section for details and limitations.

Suggested Dosage (Informational)

Common supplemental ranges used in practice and non‑AF human literature are 1–3 g/day in divided doses (e.g., morning and evening). Higher doses described in case reports (e.g., ≥6 g/day) should only be considered with clinical supervision. Start low and evaluate tolerance.

• Form: Taurine powder or capsules.
• Timing: Split dosing to improve GI comfort (e.g., 1–1.5 g twice daily).
• Stacking: Some protocols combine taurine with magnesium for membrane support; evidence for combinations in AF is limited.

Safety and Interactions

Taurine is generally well tolerated. Potential adverse effects include GI discomfort at higher intakes. Interactions are uncommon but theoretically possible with certain antihypertensives or diuretics (electrolyte balance). Patients with kidney disease, pregnancy, or complex medication regimens should obtain individualized advice.

Practical Tips

• Address triggers (alcohol, sleep, caffeine, dehydration) alongside any supplement approach.
• Monitor symptoms and resting heart rate. Wearables can help track burden trends but do not replace medical diagnostics.
• Re‑evaluate need and dose with your clinician after ablation or medication changes.

Continue reading about L‑citrulline or return to the Research overview.